Testing Flonoltinib for myelofibrosis after JAK inhibitor failure
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new tablet, Flonoltinib, for people with medium-to-high risk myelofibrosis whose prior JAK inhibitor treatment stopped working, caused side effects, or wasn't tolerated. The goal is to see if this new drug can help reduce spleen size and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have primary myelofibrosis or myelofibrosis after polycythemia vera or essential thrombocythemia, with medium-2 or high risk (or medium-1 with an enlarged spleen needing treatment).
- You have tried a JAK inhibitor (like ruxolitinib) and it didn't work well, stopped working, or caused bad side effects.
- Your spleen is enlarged—either felt below the ribcage by 5 cm or more, or measured on a scan as at least 450 cm³.
- Your blood counts are fairly stable: low blast cells (≤10%), adequate neutrophils (≥1.0), platelets (≥100), and hemoglobin (>60), and your liver and kidney function are within normal limits.
- You are expected to live more than 24 weeks and are able to care for yourself (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new pill for people with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It aims to see if the drug can help manage the disease and offer a new treatment option for those who may have limited choices.
This trial tests an oral medicine called flonoltinib maleate for people with myelofibrosis. It may help reduce an enlarged spleen and improve symptoms like fatigue and night sweats.
This trial is testing a new drug called WJ01024, which may help treat myelofibrosis. It can be taken alone or with ruxolitinib, a standard treatment for this condition. The study checks safety and how well it works.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
Hear when a new MF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.